Mikalai
★    

Belarus,
2019-12-14 14:39
(356 d 15:11 ago)

Posting: # 20975
Views: 1,637
 

 NTI drug but with high CV [Power / Sample Size]

Dear all.
What would be a sample size for a BE study when the CV of the drug is 30% but bioequivalence should be in range 90_110%? Our assumption is around 400 subject if the design is standard, and 200 if the design is replicative
Best regards.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2019-12-14 15:11
(356 d 14:39 ago)

@ Mikalai
Posting: # 20976
Views: 1,139
 

 NTI drug with high CV?

Hi Mikalai,

» What would be a sample size for a BE study when the CV of the drug is 30% but bioequivalence should be in range 90_110%?

Unless the drug belongs to the last generation anticoagulants (dabigatran, rivaroxaban) that's a contradiction. NTIDs show low variability. Otherwise, there would have been serious problems in phase III: toxicity, lacking efficacy – no approval – end of story.
BTW, the acceptance limits for NTIDs in the EEA are 90.00–111.11%.

» Our assumption is around 400 subject if the design is standard, and 200 if the design is replicative

library(PowerTOST)
sampleN.TOST(CV = 0.3, theta1 = 0.9, design = "2x2x2")
sampleN.TOST(CV = 0.3, theta1 = 0.9, design = "2x2x4")

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Activity
 Admin contact
21,240 posts in 4,431 threads, 1,482 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Saturday 05:51 UTC (Europe/Vienna)

I believe there is no philosophical high-road in science,
with epistemological signposts. No, we are in a jungle
and find our way by trial and error,
building our road behind us as we proceed.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5